On October 21, Abbott Laboratories fell 3.45% in Pre-Market Trading. The move followed the company’s announcement that it plans to separate its global nutrition business into an independent publicly traded company, with completion expected by the end of 2027 and Daniel Salvadori set to serve as chief executive officer of the new nutrition company.

At the same time, Abbott Laboratories reported quarterly adjusted EPS of $1.42, in line with expectations and up from $1.30 a year earlier, while revenue of $13.013 billion came in slightly above the $12.998 billion estimate.

The company also reaffirmed its full-year EPS guidance rather than raising it, suggesting the market focused more on portfolio separation uncertainty and execution risk than on the modest revenue beat.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)